Komori
Governance4569KYORIN Pharmaceutical Co.,Ltd.Pharmaceuticals

Report on Corporate Governance 2026/06/26

The company has a board of company auditors and a board of directors, along with voluntary committees on compensation and nominations, as its corporate governance structure. No changes from the previous report are stated.

Worth reading
59In focus
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit & Supervisory Board
Committee1
Voluntary compensation and nomination committee: proportion of outside members is 非開示
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit & Supervisory Board
CommitteeVoluntary compensation and nomination committee: proportion of outside members is Not disclosed
Items this document does not state (6)
Number of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Not stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Report on Corporate Governance 2026/06/26 | KYORIN Pharmaceutical Co.,Ltd. (4569) timely disclosure | Komori